

Aneta Szudy-Szczyrek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8307231/publications.pdf>

Version: 2024-02-01

30
papers

188
citations

1307594

7
h-index

1199594

12
g-index

30
all docs

30
docs citations

30
times ranked

286
citing authors

#	ARTICLE	IF	CITATIONS
1	ACE Insertion/Deletion Polymorphism (rs4646994) Is Associated With the Increased Risk of Multiple Myeloma. <i>Frontiers in Oncology</i> , 2019, 9, 44.	2.8	24
2	The Association of GSTT1, GSTM1, and TNF- β Polymorphisms With the Risk and Outcome in Multiple Myeloma. <i>Frontiers in Oncology</i> , 2019, 9, 1056.	2.8	20
3	Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen. <i>Annals of Hematology</i> , 2020, 99, 2881-2891.	1.8	18
4	Serum brain-derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients. <i>British Journal of Haematology</i> , 2020, 191, 77-89.	2.5	16
5	Neutrophil-to-Lymphocyte Ratio as a Factor Predicting Radiotherapy Induced Oral Mucositis in Head Neck Cancer Patients Treated with Radiotherapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 4444.	2.4	13
6	Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1109.	2.4	11
7	The Impact of the <i>NOD2/CARD15</i> Variant (3020insC) and <i>PSMA6</i> Polymorphism (-8<math>\gt;G) on the Development and Outcome of Multiple Myeloma. <i>BioMed Research International</i> , 2020, 2020, 1-15.	1.9	9
8	The impact of ACE gene polymorphism on the incidence and phenotype of sarcoidosis in rural and urban settings. <i>Archives of Medical Science</i> , 2016, 6, 1263-1272.	0.9	8
9	Polymorphisms in the promotor region of the <i>CRBN</i> gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients. <i>British Journal of Haematology</i> , 2019, 186, 695-705.	2.5	7
10	Methylation of DROSHA and DICER as a Biomarker for the Detection of Lung Cancer. <i>Cancers</i> , 2021, 13, 6139.	3.7	7
11	Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene. <i>Oncology Reports</i> , 2013, 30, 1463-1472.	2.6	6
12	Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer. <i>Pathology and Oncology Research</i> , 2017, 23, 607-614.	1.9	6
13	Polymorphisms in the promoter region of the <i>CRBN</i> gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients. <i>Oncotarget</i> , 2018, 9, 24054-24068.	1.8	6
14	microRNAs as the biomarkers of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-9.	1.3	5
15	Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy. <i>Cancers</i> , 2021, 13, 4806.	3.7	5
16	Chemotherapy-Related Differences in Cognitive Functioning and Their Biological Predictors in Patients with Multiple Myeloma. <i>Brain Sciences</i> , 2021, 11, 1166.	2.3	5
17	New prognostic biomarkers in multiple myeloma. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2016, 70, 811-819.	0.1	5
18	Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma. <i>Cells</i> , 2022, 11, 752.	4.1	4

#	ARTICLE	IF	CITATIONS
19	Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer. <i>Cells</i> , 2022, 11, 956.	4.1	4
20	The role of immune checkpoint inhibitors in prostate cancer. <i>Annals of Agricultural and Environmental Medicine</i> , 2019, 26, 120-124.	1.0	3
21	Polymorphisms in the Gene Encoding Caspase 8 May Predict the Response to First-Line Platinum-Based Chemotherapy in Locally Advanced or Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 1126.	2.4	2
22	The Relationship of ABCB1/MDR1 and CYP1A1 Variants with the Risk of Disease Development and Shortening of Overall Survival in Patients with Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2021, 10, 5276.	2.4	2
23	Chronic use of PPIs as a potential cause of anemia: case reports and review of the literature. <i>Acta Haematologica Polonica</i> , 2020, 51, 108-111.	0.3	1
24	Autologous stem cell transplantation in the treatment of multiple myeloma patients with 17p deletion. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 106-111.	0.4	1
25	THE EFFICACY OF COMBINATION THERAPY WITH LENALIDOMIDE AND DEXAMETHASONE IN THE TREATMENT OF RELAPSED MULTIPLE MYELOMA. <i>Health Problems of Civilization</i> , 2015, 2, 50-54.	0.1	0
26	Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review. <i>Annals of Agricultural and Environmental Medicine</i> , 2021, 29, 103-109.	1.0	0
27	Description of invariant NKT cells. <i>Journal of Education, Health and Sport</i> , 2021, 11, 417-422.	0.1	0
28	Zaawansowana mastocytoza układowa – stanowisko eksperta w dotychczasowej postępowania diagnostycznego i leczniczego. <i>Hematologia</i> , 2019, 10, 113-123.	0.0	0
29	Differentiation of metastatic lesions to the bones and multiple myeloma – a case study. <i>Journal of Education, Health and Sport</i> , 2020, 10, 28.	0.1	0
30	Diagnostyka i leczenie mastocytozy układowej – stanowisko eksperta. <i>Hematologia</i> , 2020, 11, 61-72.	0.0	0